← Eichor
Study identifier: NCT05818774 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

End-on Versus Parallel Radiofrequency Lesioning for Neurotomy of the Cervical Medial Branch Nerves

Condition: Neck Pain · Zygapophyseal Joint Arthritis  ·  Sponsor: University Health Network, Toronto

PhaseNA
Planned participants72
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Aim of the EndPaRL study is to compare the efficacy and effectiveness of the two techniques utilizing sharp straight conventional radiofrequency needle with a trident needle for radiofrequency neurotomy of Cervical Medial Branch Nerves (CMBNs), in patients presenting with chronic, moderate-to-severe, neck pain due to cervical zygapophyseal joint osteoarthritis, as diagnosed by positive responses to two consecutive diagnostic blocks with local anesthetic of the CMBN.

This description comes directly from the study's public registry record.

Talk to the study team

Danielle Alvares, PhD  ·  (416) 603-5800  ·  danielle.alvares@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (3)

Women's College HospitalToronto, Ontario, CanadaRecruiting
University Health Network (UHN)Toronto, Ontario, CanadaRecruiting
Division of Pain Medicine, Department of Anesthesiology, Reanimation, and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona.Barcelona, Catalonia, SpainNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05818774